Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV005041972 | SCV005683543 | pathogenic | Exostoses, multiple, type 2; Seizures-scoliosis-macrocephaly syndrome | 2024-01-08 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000002579 | SCV000022737 | pathogenic | Exostoses, multiple, type 2 | 1997-09-01 | no assertion criteria provided | literature only | |
Prevention |
RCV003894785 | SCV004711505 | pathogenic | EXT2-related disorder | 2023-11-27 | no assertion criteria provided | clinical testing | The EXT2 c.666C>G variant is predicted to result in premature protein termination (p.Tyr222*). This variant has been reported in several affected members of a family with hereditary multiple osteochondromas (Family 2, Philippe et al. 1997. PubMed ID: 9326317), and also in an individual from an unrelated family with hereditary multiple osteochondromas (Li et al. 2018. PubMed ID: 30334991. This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Nonsense variants in EXT2 are expected to be pathogenic. This variant is interpreted as pathogenic. |